Jia-horng H. Kao
Experienced in Folliculitis

Jia-horng H. Kao

Gastroenterology
7 Chung Shan South Road, 
TPQ, TW 
Experienced in Folliculitis
7 Chung Shan South Road, 
TPQ, TW 
OverviewLocationsClinical Research

Overview

Jia-horng Kao is a Gastroenterologist in Taiwan. Mr. Kao is rated as an Experienced expert by MediFind in the treatment of Folliculitis. His top areas of expertise are Hepatitis, Hepatitis B, Hepatitis C, Hepato-Pancreato-Biliary Surgery, and Liver Transplant.

His clinical research consists of co-authoring 510 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Folliculitis.

Specialties
Gastroenterology
Gender
Male

Locations

7 Chung Shan South Road, TPQ 10002, Taiwan
Other Locations
1 Chang Te Street, TPQ 10048, Taiwan
National Taiwan University Hospital Bei Hu Branch
TPQ, Taiwan
Yunlin Branch, Douliu, TNQ, Taiwan
7 Chung Shan South Road, 100, TPQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Exploratory Study to Evaluate The Efficacy And Safety of HLX10, A Humanized Monoclonal Antibody Targeting Programmed Death-1 (PD-1) Protein In Chronic Hepatitis B Patients
An Exploratory Study to Evaluate The Efficacy And Safety of HLX10, A Humanized Monoclonal Antibody Targeting Programmed Death-1 (PD-1) Protein In Chronic Hepatitis B Patients
Enrollment Status: Unknown
Publish Date: October 20, 2020
Intervention Type: Drug
Study Drugs: Recombinant anti-programmed death-1 humanized monoclonal antibody, Nucleoside/Nucleotide analogues
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects
A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects
Enrollment Status: Completed
Publish Date: October 01, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Randomized, Multiple-dose, Double-blind, Placebo-controlled Study of JKB-122 to Assess Liver Tests in HCV Subjects Who Have Been Nonresponsive to Prior Interferon Based Therapies Either Alone or in Combination With Ribavirin
A Phase 2, Randomized, Multiple-dose, Double-blind, Placebo-controlled Study of JKB-122 to Assess Liver Tests in HCV Subjects Who Have Been Nonresponsive to Prior Interferon Based Therapies Either Alone or in Combination With Ribavirin
Enrollment Status: Terminated
Publish Date: July 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Enrollment Status: Completed
Publish Date: March 11, 2020
Intervention Type: Drug
Study Phase: Phase 4
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Enrollment Status: Completed
Publish Date: July 19, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 4 Less Clinical Trials

510 Total Publications

Highlights.
Highlights.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: October 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kao's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile